CSIMarket
 


Beam Therapeutics Inc   (BEAM)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

BEAM's Capital Expenditures Growth by Quarter and Year

Beam Therapeutics Inc 's Capital Expenditures results by quarter and year




BEAM Capital Expenditures (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December 8.13 -128.50 -39.60 23.10
III Quarter September 2.82 - 35.70 -8.80
II Quarter June 2.37 30.90 31.30 -1,141.10
I Quarter March 3.05 31.00 34.90 57.00
FY   16.37 -66.60 62.30 -1,069.80



BEAM Capital Expenditures forth quarter 2020 Y/Y Growth Comment
Beam Therapeutics Inc in the forth quarter achieved Capital Expenditures of $ 8.13 millions compare to Capital Expenditures recorded in same quarter a year ago.

According to the results reported in the forth quarter, Beam Therapeutics Inc achieved the best Capital Expenditures growth in Biotechnology & Drugs industry. While Beam Therapeutics Inc ' s Capital Expenditures no change of % ranks overall at the positon no. 0 in the forth quarter.




BEAM Capital Expenditures ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - - - -35.47 %
III Quarter September - - - -
II Quarter June -92.33 % -1.28 % - -
I Quarter March -90.16 % -11.17 % -38.77 % -
FY   - - - -

Financial Statements
Beam Therapeutics Inc 's forth quarter 2020 Capital Expenditures $ 8.13 millions BEAM's Income Statement
Beam Therapeutics Inc 's forth quarter 2019 Capital Expenditures $ -128.50 millions Quarterly BEAM's Income Statement
New: More BEAM's historic Capital Expenditures Growth >>


BEAM Capital Expenditures (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December 188.12 % - - -
III Quarter September 18.99 % - 14.06 % -
II Quarter June -22.3 % -0.32 % -10.32 % -
I Quarter March - - 51.08 % 59.22 %
FY (Year on Year)   - - - -




Capital Expenditures forth quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #0

Capital Expenditures Y/Y Growth Statistics
High Average Low
19.39 % -31.06 % -100 %
(March 31, 2010)   (Dec 31 2013)
Capital Expenditures forth quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #0
Capital Expenditures Y/Y Growth Statistics
High Average Low
19.39 % -31.06 % -100 %
(March 31, 2010)   (Dec 31 2013)

Capital Expenditures by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Beam Therapeutics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
188.22 % 12.19 % -100 %
(Dec 31 2020)  


BEAM's IV. Quarter Q/Q Capital Expenditures Comment
Beam Therapeutics Inc achieved in the IV. Quarter 2020 above company average sequential Capital Expenditures doubling of 188.12%, to $ 8.13 millions, from $2.82 millions in the third quarter.
BEAM is impressively improving, with claiming better then regular increase, and additionally accelerating pace.

Within Biotechnology & Drugs industry 19 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Beam Therapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 296.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #20
Healthcare Sector #78
Overall #296
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #20
Healthcare Sector #78
Overall #296
Capital Expenditures Q/Q Growth Statistics
High Average Low
188.22 % 12.19 % -100 %
(Dec 31 2020)  


BEAM's IV. Quarter Q/Q Capital Expenditures Comment
Beam Therapeutics Inc achieved in the IV. Quarter 2020 above company average sequential Capital Expenditures doubling of 188.12%, to $ 8.13 millions, from $2.82 millions in the third quarter.
Biotechnology & Drugs company is undergoing a remarkable growth, not only claiming better then regular growth, but also increasing speed, Paulo Batatel Almeida, Biotechnology & Drugs industry insider from Lisbon mentioned.

Within Biotechnology & Drugs industry 19 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Beam Therapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 296.


Beam Therapeutics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec. 30, 2014)
Cumulative Capital Expenditures 12 Months Ending $ 16.36 $ -120.27 $ 0.00 $ 0.00 $ 0.00
Y / Y Capital Expenditures Growth (TTM) - - - - -
Year on Year Capital Expenditures Growth Overall Ranking # # # # #
Seqeuential Capital Expenditures Change (TTM) - - - - -
Seq. Capital Expenditures Growth (TTM) Overall Ranking # # # # #




Cumulative Capital Expenditures growth Comment


Beam Therapeutics Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
130.12 %
2.95 %
-50.16 %
(June 30. 2011)  

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall # 0

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
-0.31 %
-43.11 %
-72.59 %
(June 30. 2011)  


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 # 0
Cumulative Capital Expenditures growth Comment


Beam Therapeutics Inc achieved highest trailing twelve month year on year Capital Expenditures growth. While overall Capital Expenditures growth ranking, remained unchanged compare to the previous quarter at no. .

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
130.12 %
2.95 %
-50.16 %
(June 30. 2011)  


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall # 0

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
-0.31 %
-43.11 %
-72.59 %
(June 30. 2011)  


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 # 0




Other Capital Expenditures Growth
Biotechnology & Drugs Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
BEAM's Capital Expenditures Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for BEAM's Competitors
Capital Expenditures Growth for Beam Therapeutics Inc 's Suppliers
Capital Expenditures Growth for BEAM's Customers

You may also want to know
BEAM's Annual Growth Rates BEAM's Profitability Ratios BEAM's Asset Turnover Ratio BEAM's Dividend Growth
BEAM's Roe BEAM's Valuation Ratios BEAM's Financial Strength Ratios BEAM's Dividend Payout Ratio
BEAM's Roa BEAM's Inventory Turnover Ratio BEAM's Growth Rates BEAM's Dividend Comparisons



Companies with similar Capital Expenditures doubling for the quarter ending Dec 31 2020 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2020
Emergent Biosolutions Inc -0.28%$ -0.277 millions
Arrowhead Pharmaceuticals Inc -1.13%$ -1.128 millions
Bausch Health Companies Inc -1.18%$ -1.176 millions
Inogen Inc -1.65%$ -1.650 millions
Seres Therapeutics Inc -1.74%$ -1.739 millions
Nuvasive Inc-1.87%$ -1.866 millions
Cerus Corporation-1.89%$ -1.895 millions
Pra Health Sciences Inc -2.29%$ -2.293 millions
Steris Plc-3.12%$ -3.118 millions
Theravance Biopharma inc -4.53%$ -4.528 millions
Sientra inc -5.16%$ -5.163 millions
Zosano Pharma Corporation-5.48%$ -5.481 millions
Quest Diagnostics Inc-5.81%$ -5.814 millions
Taro Pharmaceutical Industries Ltd-7.40%$ -7.398 millions
Option Care Health Inc -7.52%$ -7.516 millions
Xeris Pharmaceuticals Inc -7.79%$ -7.787 millions
Amgen Inc -7.98%$ -7.979 millions
Zoetis Inc -8.43%$ -8.434 millions
Urogen Pharma Ltd -10.42%$ -10.417 millions
Gilead Sciences Inc -10.84%$ -10.837 millions
Evelo Biosciences Inc -11.66%$ -11.663 millions
Abbvie Inc -11.99%$ -11.987 millions
Fate Therapeutics inc -12.28%$ -12.278 millions
Tabula Rasa Healthcare inc -12.64%$ -12.635 millions
Abiomed Inc -12.78%$ -12.775 millions
Seagen Inc -13.06%$ -13.060 millions
Lemaitre Vascular Inc-13.21%$ -13.214 millions
Molecular Templates Inc -13.25%$ -13.253 millions
Phibro Animal Health Corp-13.29%$ -13.294 millions
Syneos Health Inc -13.59%$ -13.588 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

HZN's Profile

Stock Price

HZN's Financials

Business Description

Fundamentals

Charts & Quotes

HZN's News

Suppliers

HZN's Competitors

Customers & Markets

Economic Indicators

HZN's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071